Favorable Press Coverage Somewhat Likely to Affect CEL-SCI (CVM) Stock Price

Headlines about CEL-SCI (NYSEMKT:CVM) have trended positive recently, according to Alpha One Sentiment. The research group, a division of Accern, ranks the sentiment of news coverage by monitoring more than 20 million blog and news sources in real time. Alpha One ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores nearest to one being the most favorable. CEL-SCI earned a news sentiment score of 0.29 on Alpha One’s scale. Alpha One also assigned news articles about the company an impact score of 60 out of 100, indicating that recent news coverage is somewhat likely to have an impact on the company’s share price in the near future.

Here are some of the media stories that may have effected AlphaOne Sentiment Analysis’s analysis:

Shares of CEL-SCI (NYSEMKT:CVM) traded up 0.000% during mid-day trading on Friday, reaching $0.107. The company had a trading volume of 752,370 shares. The stock’s 50-day moving average price is $0.10 and its 200 day moving average price is $0.13. The company’s market capitalization is $20.43 million. CEL-SCI has a 1-year low of $0.06 and a 1-year high of $0.56.

CEL-SCI (NYSEMKT:CVM) last issued its quarterly earnings data on Wednesday, May 10th. The company reported ($0.05) EPS for the quarter. The business had revenue of $0.02 million during the quarter. Equities analysts expect that CEL-SCI will post ($0.42) EPS for the current year.

WARNING: This report was first reported by Sports Perspectives and is owned by of Sports Perspectives. If you are accessing this report on another website, it was stolen and republished in violation of United States & international trademark and copyright legislation. The legal version of this report can be viewed at https://sportsperspectives.com/2017/05/19/cel-sci-cvm-receives-media-impact-rating-of-0-29-updated-updated.html.

CEL-SCI Company Profile

CEL-SCI Corporation is engaged in the research and development at developing the treatment of cancer and other diseases by using the immune system. The Company is focused on activating the immune system to fight cancer and infectious diseases. It operates through the segment of research and development of certain drugs and vaccines.

Receive News & Ratings for CEL-SCI Co. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CEL-SCI Co. and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply